Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
about
Stroke prevention in diabetes and obesityAngiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axisA combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention.Primary stroke prevention and hypertension treatment: which is the first-line strategy?The renin angiotensin aldosterone system and insulin resistance in humans.The Impact of Metabolic Syndrome, Homocysteine, and B Vitamins on Carotid Artery Intima-Media Thickness in Hypertensive PatientsThe renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studiesEffects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC studyAngiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.Compliance with dietary guidelines affects capillary recruitment in healthy middle-aged men and women.Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.Do all antihypertensive drugs improve carotid intima-media thickness? A network meta-analysis of randomized controlled trials.Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial)
P2860
Q28200179-1DB7C190-CA20-40EC-867D-CC01DA836073Q34004063-331E04A2-3F48-46F5-89F3-2F34980F08C0Q34018990-DA5D6683-A46E-48F7-B344-48332335BE19Q35513559-C550B3F2-A548-4B32-8E59-B0657BF37EBDQ36550987-F048F6B0-19DE-49DC-83C0-2F47BFA5DCA4Q36721716-7979F765-C048-4443-88AB-65D37B2DA92AQ37158159-B18FE15C-CE34-4A78-80F8-21E376D19A8FQ37167569-2721BEE0-7E62-4C23-BEEA-F841BEB3ABC4Q37427232-2DF61BF6-E1A4-4ABD-BA56-0FC77ABA8AA8Q37694278-97FE2239-9FFA-40E7-AB65-948E2FE738C6Q38007893-D5FA67CE-29D2-40BD-A2EE-87E18860599EQ38497180-FED89815-6F29-4716-98AD-13BA88C4A9C0Q43886848-17EE9990-1559-4F63-AC50-D9C6166C1D95Q46174552-7C2A40AE-360C-4C91-84E7-FADE2EA8A81CQ46979873-6A61D041-F950-4622-800A-5D7CFC43E337Q57816063-A203ECD6-D9C3-4F71-A376-D1B341D60D6B
P2860
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Losartan but not atenolol redu ...... hypertension. A LIFE substudy.
@en
Losartan but not atenolol redu ...... hypertension. A LIFE substudy.
@nl
type
label
Losartan but not atenolol redu ...... hypertension. A LIFE substudy.
@en
Losartan but not atenolol redu ...... hypertension. A LIFE substudy.
@nl
prefLabel
Losartan but not atenolol redu ...... hypertension. A LIFE substudy.
@en
Losartan but not atenolol redu ...... hypertension. A LIFE substudy.
@nl
P2093
P2860
P1433
P1476
Losartan but not atenolol redu ...... hypertension. A LIFE substudy.
@en
P2093
Hans Ibsen
Harriet Dige-Petersen
Jens Rokkedal
Jonathan N Bella
Keld Neland
Kristian Wachtell
Michael H Olsen
P2860
P304
P356
10.1080/08037050510034185
P577
2005-01-01T00:00:00Z